60 results
8-K
HARP
Harpoon Therapeutics Inc
26 Jan 24
Other Events
12:00am
Therapeutics, Inc., a Delaware corporation (“Harpoon”), presented a clinical update at the American Society of Clinical Oncology (“ASCO
8-K
EX-99.1
HARP
Harpoon Therapeutics Inc
9 Nov 23
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
1 monotherapy dose escalation cohorts.
In October, Harpoon reported favorable interim monotherapy data in a poster session at the European Society … at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego.
In September, HPN217
8-K
HARP
Harpoon Therapeutics Inc
23 Oct 23
Other Events
8:00am
evaluating HPN328 in small cell lung cancer and other neuroendocrine tumor types at the European Society of Medical Oncology Congress (ESMO) 2023.
A copy
8-K
HARP
Harpoon Therapeutics Inc
13 Sep 23
Termination of a Material Definitive Agreement
4:15pm
myeloma. The presentation will take place on September 28, 2023 at the 20th International Myeloma Society (IMS) Annual Meeting being held in Athens … targeting ProTriTAC™, and plans to present the interim Phase 1/2 clinical data from HPN328 at European Society for Medical Oncology (ESMO) being held
8-K
EX-99.1
0zb3s5on06w vh9g6z
9 Aug 23
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:25pm
8-K
EX-99.1
2cso sokn65ce
11 May 23
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
9:07pm
PRE 14A
f0wjr nrgzojar
14 Apr 23
Preliminary proxy
4:54pm
8-K
c0v0ii8v9j84 6tryp
12 Dec 22
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
4:03pm
8-K
EX-99.1
9qlrrcdp
12 Dec 22
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
4:03pm
8-K
EX-99.1
me4bci dz
14 Nov 22
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
5:17pm
8-K
EX-99.1
fus6t6hk1ppk
10 Aug 22
Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:14pm
8-K
jwv oblpdy
3 Jun 22
Regulation FD Disclosure
5:05pm
8-K
EX-99.1
gd88jwnumro5x38qo
12 May 22
Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:28pm